The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?
Open accessAbstract
Sodium–glucose co-transporter-2 (SGLT2) inhibitors improve cardiovascular and renal outcomes in patients with type 2 diabetes, including those with diabetic kidney disease. However, the US Food and Drug Administration and European Medicines Agency warnings about potential adverse effects, such as urosepsis and pyelonephritis, based on post-marketing case reports, may deter physicians from prescribing these drugs. A recent evaluation of two large US-based databases of commercial claims failed to find evidence for an increased risk of urinary tract infection (UTI) or severe UTI in type 2 diabetes patients who were prescribed an SGLT2.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Health disparities in Black patients with diabetes and CKD have been well documented.
“Health disparities in Black patients with diabetes and CKD have been well documented.”
From Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States (2023) · cites this paper as [28]
The paper’s Abstract discusses diabetes, CKD, and SGLT2 inhibitors, but not health disparities in Black patients. Searches for Black patients, African Americans, and racial disparities found no passage addressing the claim; no page numbers are available in our copy. (LLM, conf=0.76)
Experimental — accuracy not yet measuredThe Coronary Artery Risk Development in Young Adults study found that Black patients had significantly faster annualized estimated glomerular filtration rates of decline.
“The Coronary Artery Risk Development in Young Adults study found that Black patients had significantly faster annualized estimated glomerular filtration rates of decline.28”
From Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States (2023) · cites this paper as [28]
The paper’s Abstract discusses SGLT2 inhibitors, urinary tract infections, and kidney protection, but does not report findings from the Coronary Artery Risk Development in Young Adults study. Searches for that study and for racial differences in annualized eGFR decline found no relevant passage in our copy. (LLM, conf=0.75)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · see citing works
Saliba, W., Nitzan, O., Chazan, B., & Elias, M. (2015) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s51792 · Cited by 345 · see citing works
Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy090 · Cited by 237 · see citing works
Flagged first, then by citations
Research works printed but not linked: 11
- [2]Kramer A, Pippias M, Noordzij M et al The European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. Clin Kidney J 2018; 11: 108– 122 29423210 PMC5798130
- [3]Loutradis C, Papadopoulou E, Theodorakopoulou M et al The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. Future Med Chem 2019; 11: 1285– 1303 31161798
- [4]Sarafidis P, Ferro CJ, Morales E et al SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant 2019; 34: 208– 230 30753708
- [6]Fernandez-Fernandez B, Fernandez-Prado R, Górriz JL et al Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? Clin Kidney J 2019; 12: 313– 321 31198532 PMC6543971
- [7]Davies MJ, D'Alessio DA, Fradkin J et al Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41: 2669– 2701 30291106 PMC6245208
- [10]Neal B, Perkovic V, Mahaffey KW et al Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644– 657 28605608
- [11]Wiviott SD, Raz I, Bonaca MP et al Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347– 357 30415602
- [13]Davis-Ajami ML, Pakyz A, Wu J et al A payer perspective of the costs of urinary tract and skin and soft tissue infections in adults with diabetes and the relationship to oral antidiabetic medication nonadherence. J Manag Care Spec Pharm 2019; 25: 1409– 1419 31436479 PMC10397633
- [18]Puckrin R, Saltiel MP, Reynier P et al SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 2018; 55: 503– 514 29484489
- [19]Dave CV, Schneeweiss S, Kim D et al Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections. A population-based cohort study. Ann Intern Med 2019; 171: 248– 256 PMC6989379 31357213
- [20]Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA 2016; 316: 1818– 1819 27802529
Cited by
Sorted by citations
Zhao, J. Z., Weinhandl, E. D., Carlson, A. M., & St. Peter, W. L. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2022.100564 · Cited by 33 · see citing works
“It may be that physicians are reluctant to start SGLT2i in women because of concern of increased risk of urinary tract infections (UTIs), but this has been refuted in a recent meta-analysis.(31) The 2 clinical”
Result
- Authors
- Sarafidis, P. A., & Ortiz, A.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- IIS-Fundacion Jimenez Diaz, School of Medicine, University Autonoma of Madrid, FRIAT and REDINREN, Madrid, Spain
- Corresponding author
- Sarafidis, Pantelis A
- Venue
- Clinical Kidney Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-18
- Volume
- 13
- Issue
- 1
- Pages
- 24-26
- ISSN
- 2048-8505 (ISSN-L)
- 2048-8513
- PMC
- PMC7025347
- OpenAlex
- W2996314687
- Cited by
- 37
- References
- 4
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 12 · 2023: 6 · 2022: 4 · 2021: 4 · 2020: 4
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Kidney Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Hispana (submittedVersion)
- Biblos-e Archivo (Universidad Autónoma de Madrid) (submittedVersion, public-domain)
- Funders
- A.O (FIS PI16/02057, PI19/00588, PI19/00815, DTS18/00032, ERA-PerMed-JTC2018, KIDNEY ATTACK AC18/00064, PERSTIGAN AC18/00071, ISCIII-RETIC REDinREN RD016/0009)
- Sociedad Española de Nefrología (B2017/BMD-3686 CIFRA2-CM)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Epidemiology › Urinary Tract Infections Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- SGLT2 inhibitors, urinary tract infection, type 2 diabetes, drug safety, urosepsis, pyelonephritis, adverse drug reactions, commercial claims data
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
